KINSHASA, Democratic Republic of the Congo — In a monumental leap for global health security, a major international consortium has officially inaugurated the PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) clinical trial. The study, which began patient enrollment today, marks the first concerted global effort to identify life-saving therapeutics specifically for the Bundibugyo virus (BVD), a virulent and often fatal strain of the Ebola virus family.
As the Democratic Republic of the Congo (DRC) battles a persistent and deadly outbreak, the launch of this trial represents a shift in how the international community responds to infectious disease crises. By integrating rigorous scientific research directly into the heart of an active outbreak, the PARTNERS trial aims to transform clinical care from reactive, supportive measures to proactive, evidence-based intervention.
The Core Objective: Challenging a Deadly Pathogen
The Bundibugyo virus remains one of the most enigmatic and dangerous members of the Ebolavirus genus. Unlike other strains for which vaccines and treatments have been developed, BVD has historically lacked specific, clinically approved therapeutics. To date, nearly 1,400 people have been diagnosed with the disease in the DRC, with the death toll climbing toward 440. While approximately 210 individuals have successfully recovered, the disparity between infections and outcomes highlights the desperate need for targeted medical intervention.
The PARTNERS trial is designed to evaluate two primary antiviral candidates:
- MBP134: A potent monoclonal antibody treatment.
- Remdesivir: A broad-spectrum antiviral medication that has shown promise in various viral contexts.
Beyond testing these treatments individually, the trial’s adaptive platform allows researchers to investigate whether a combination of these therapies provides a synergistic survival benefit. By deploying a “platform trial” design, the WHO-led consortium has ensured that the study remains agile; as new therapeutic candidates emerge, they can be seamlessly integrated into the trial protocol following rigorous safety assessments by the WHO Technical Advisory Group.
Chronology of the Crisis and Research Response
The urgency of the PARTNERS trial is underscored by the trajectory of the current outbreak.
- Early Detection: Following the initial emergence of BVD, local health authorities in the DRC, supported by the Institut National de Recherche Biomédicale (INRB), identified a significant spike in cases, characterizing a localized but high-fatality epidemic.
- Scientific Mobilization: Recognizing that existing Ebola treatments were not specifically indicated for BVD, the WHO convened a Technical Advisory Group to review the global landscape of preclinical research.
- Strategic Planning: In record time, the WHO, the University of Oxford’s Pandemic Sciences Institute, and the INRB established the logistical framework for a randomized, controlled clinical trial. This effort was bolstered by the logistical and humanitarian expertise of organizations such as ALIMA (The Alliance for International Medical Action) and Médecins Sans Frontières (MSF).
- Trial Launch: Today, the transition from paper to patient has been completed, with the first participants being enrolled at specialized treatment units across the affected regions in the DRC.
A New Paradigm in Clinical Research
Historically, the delay between the start of an outbreak and the initiation of clinical trials has cost thousands of lives. The PARTNERS trial seeks to dismantle this traditional "research-after-the-fact" model.
"One of the key lessons from recent outbreaks is that research needs to happen alongside the response, not after it," explains Professor Amanda Rojek, PARTNERS Trial Operations Lead and Associate Professor of Health Emergencies at the Pandemic Sciences Institute. "The PARTNERS trial gives us an opportunity to evaluate potential treatments during the outbreak itself, so that the evidence generated can help inform patient care when it is needed most—in months rather than years."
This sentiment is echoed by Prof. Jean-Jacques Muyembe-Tamfum, Director-General of the INRB, who emphasizes the integration of research into routine clinical practice. By providing patients with access to investigational treatments while simultaneously collecting high-quality data, the trial avoids the ethical dilemma of "research versus care," instead positioning research as a central pillar of patient support.
Supporting Data and Patient Care Protocols
The trial is not merely about testing drugs; it is about raising the standard of care for all affected individuals. Every patient enrolled in the study receives comprehensive, early supportive care that aligns with the highest international standards. This includes:
- Fluid and Electrolyte Management: Aggressive oral or intravenous rehydration to combat the severe dehydration characteristic of the virus.
- Oxygen and Respiratory Support: Ensuring stabilization for patients suffering from respiratory distress.
- Hemodynamic Monitoring: Managing blood pressure and providing specialized pain control.
These protocols are supported by an independent data and safety monitoring board, which will provide ongoing oversight to ensure the safety of all participants throughout the 28-day follow-up period. This rigorous oversight ensures that any signal of success—or concern—is identified immediately, allowing for real-time adjustments to the trial protocol.
Official Responses: A Global Coalition
The scale of this operation has required unprecedented coordination between the DRC government and international partners.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General:
"Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit. The PARTNERS trial, established with national authorities and scientific partners in record time, offers real hope that we can deliver concrete results for—and with—the communities at the heart of the outbreak."
Dr. Samuel Roger Kamba, Minister of Health of the DRC:
"In responding to Bundibugyo virus disease, the Democratic Republic of the Congo is demonstrating its strong commitment to science and research. The launch of the PARTNERS clinical trial represents a significant step forward, offering renewed hope to patients, their families, and affected communities. Findings from this study could contribute to identifying more effective therapeutic options, helping to save lives during the current outbreak while strengthening global preparedness for future Ebola epidemics."
Implications for Future Outbreaks
The significance of the PARTNERS trial extends well beyond the current BVD outbreak. By creating a sustainable research platform, the consortium is building a "plug-and-play" infrastructure that can be activated for future filovirus emergencies, including other forms of Ebola and Marburg disease.
Strengthening Global Preparedness
The trial serves as a blueprint for rapid response. It highlights the importance of:
- Local Leadership: Placing the INRB at the center of the trial empowers local institutions to lead their own health security initiatives.
- Collaborative Infrastructure: Utilizing the combined strengths of academic institutions like the University of Oxford and humanitarian giants like MSF and ALIMA ensures that high-level science is delivered with grassroots operational efficiency.
- Adaptive Methodology: The flexibility of the platform trial ensures that global research remains ahead of the curve, rather than reacting to the static nature of older, less-efficient trial designs.
As the trial progresses, the eyes of the international medical community will be fixed on the DRC. The data generated over the coming months will not only define the prognosis for BVD patients but will also provide a definitive answer on the utility of monoclonal antibodies and remdesivir against this specific pathogen.
In the face of a terrifying disease, the PARTNERS trial serves as a testament to what is possible when political will, scientific rigor, and humanitarian action converge. It represents a promise to the people of the DRC—and to the world—that science will remain the foundation of our defense against the next pandemic.
About the Organizing Bodies
- INRB: The national biomedical research institution of the DRC, serving as the frontline agency for disease identification and translational research.
- Pandemic Sciences Institute (PSI), University of Oxford: An interdisciplinary hub dedicated to creating practical, equitable solutions to infectious disease threats through scientific innovation.
- World Health Organization (WHO): The United Nations agency responsible for international public health, leading global efforts to prevent disease and coordinate emergency responses.
For further information, please contact the WHO Media Team or the University of Oxford News Office.
About the Author
